Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer Question: Why does it take so long for the FDA to approve new drugs? Answer: Whenever a new cancer drug is created, it [...]
Question: My doctor told me that I had EGFR-positive lung cancer. How can I learn more about this biomarker type? Answer: EGFR epidermal growth factor receptor is a gene found in cells. It is important because it sends the [...]
By Renee Botello, MSc, Treatment and Trials Navigator Palliative care is an area of medicine that focuses on treating the person by managing the symptoms or problems caused by a disease and/or its treatment. By recognizing health problems and [...]
By Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer This blog post kicks off our series, "Understanding Lung Cancer," which simplifies the science behind lung cancer. Our goal is to provide a deeper understanding [...]
On December 27, 2024, the U.S. Food and Drug Administration (FDA) approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous injection, commonly known as a shot. This approval included all the same uses of Opdivo (nivolumab) that the FDA previously approved [...]
On Dec. 18, 2024, the U.S. Food and Drug Administration (FDA) approved Ensacove (ensartinib) for people with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have an ALK mutation and have not previously received an ALK-targeted therapy. [...]
On Dec. 4, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Bizengri (zenocutuzumab-zbco) for people with metastatic non-small cell lung cancer (NSCLC) who have an NRG1 mutation following progression on or after prior systemic therapy. [...]
On December 4, 2024, the U.S. Food and Drug Administration (FDA) approved the use of Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease did not progress following combination platinum-based chemotherapy and radiation. Previously approved [...]
Matthew Reiss MSE PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer, and Jared Weiss MD, Section Chief of Thoracic and Head & Neck Oncology, Professor of Medicine, University of North Carolina at Chapel Hill It is [...]
By Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation; Andrew Ciupek, PhD, Associate Director, Clinical Research; Shanada Monestime, PharmD, BCOP, Director, Community Engaged Research; Heather Law, MA, Associate Director, Lung Cancer Registry; Richard Erwin, Executive Director of the [...]